Correlation of CXCR4 expression with clinicopathological characteristics and prognosis of patients with non-small cell lung cancer: a Meta-analysis

Q4 Medicine

肿瘤研究与临床 Pub Date : 2020-02-28 DOI:10.3760/CMA.J.ISSN.1006-9801.2020.02.009

Qian Liu, Jian-hua Tang, Zhihua Zhang

{"title":"Correlation of CXCR4 expression with clinicopathological characteristics and prognosis of patients with non-small cell lung cancer: a Meta-analysis","authors":"Qian Liu, Jian-hua Tang, Zhihua Zhang","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.009","DOIUrl":null,"url":null,"abstract":"Objective \nTo systematically evaluate the relationship between CXCR4 and the clinicopathological characteristics and prognosis of patients with non-small cell lung cancer (NSCLC). \n \n \nMethods \nThe PubMed, EMbase, Cochrane Library, CNKI, Wanfang and China Biology Medicine databases were searched by the computer to collect the publicly published cohort studies on the correlation between CXCR4 expression and prognosis of NSCLC. The retrieval time was from the establishment of the database to May 31, 2018. Literature screening, data extraction and risk of bias were performed independently by two reviewers, and Meta-analysis was performed by using Stata 12.0 software. \n \n \nResults \nFinally, 20 studies were included, with a total of 2 124 NSCLC patients. The positive expression rate of CXCR4 in patients with adenocarcinoma was 51.8% (337/650) and it was 50.3% (224/445) in patients with squamous cell carcinoma, the difference was statistically significant (RR=1.22, 95% CI 1.09-1.38, P=0.001). The positive expression rate of CXCR4 in patients with stageⅠ-Ⅱ was 41.1% (317/772), and the rate was 57.0% (348/610) in patients with stage Ⅲ-Ⅳ, the difference was statistically significant (RR=0.62, 95% CI 0.55-0.69, P < 0.01). The positive expression rate of CXCR4 in patients with distant metastasis was 55.3% (268/485), and the positive rate of CXCR4 in those without distant metastasis was 39.2% (256/653), the difference was statistically significant (RR=1.78, 95% CI 1.54-2.06, P < 0.01). The expression of CXCR4 was not related to the size and invasion of the primary tumor, the positive expression rates of CXCR4 in T1-T2 and T3-T4 patients were 41.0%(215/524) and 53.8%(84/156) (RR=0.71, 95% CI 0.60-0.84, P=0.053). The overall survival rate of patients with CXCR4-positive was lower than that of patients with CXCR4-negative, and the difference was statistically significant (30.1% vs. 66.9%, RR=0.45, 95% CI 0.30-0.61, P < 0.01). The disease-free survival rate of patients with CXCR4-positive was lower than that of patients with CXCR4-negative (38.0% vs. 20.1%, RR=1.89, 95% CI 1.45-2.47, P=0.002). \n \n \nConclusions \nThe pathological type, tumor staging and distant metastasis of NSCLC patients are correlated with CXCR4 expression level. The expression level of CXCR4 in tumor tissues has a predictive value for the prognosis of NSCLC patients; and the higher the expression level of CXCR4 is, the lower the overall survival and disease-free survival rates are. \n \n \nKey words: \nCarcinoma, non-small-cell lung; CXCR4; Prognosis; Meta-analysis","PeriodicalId":9505,"journal":{"name":"肿瘤研究与临床","volume":"32 1","pages":"111-118"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"肿瘤研究与临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To systematically evaluate the relationship between CXCR4 and the clinicopathological characteristics and prognosis of patients with non-small cell lung cancer (NSCLC). Methods The PubMed, EMbase, Cochrane Library, CNKI, Wanfang and China Biology Medicine databases were searched by the computer to collect the publicly published cohort studies on the correlation between CXCR4 expression and prognosis of NSCLC. The retrieval time was from the establishment of the database to May 31, 2018. Literature screening, data extraction and risk of bias were performed independently by two reviewers, and Meta-analysis was performed by using Stata 12.0 software. Results Finally, 20 studies were included, with a total of 2 124 NSCLC patients. The positive expression rate of CXCR4 in patients with adenocarcinoma was 51.8% (337/650) and it was 50.3% (224/445) in patients with squamous cell carcinoma, the difference was statistically significant (RR=1.22, 95% CI 1.09-1.38, P=0.001). The positive expression rate of CXCR4 in patients with stageⅠ-Ⅱ was 41.1% (317/772), and the rate was 57.0% (348/610) in patients with stage Ⅲ-Ⅳ, the difference was statistically significant (RR=0.62, 95% CI 0.55-0.69, P < 0.01). The positive expression rate of CXCR4 in patients with distant metastasis was 55.3% (268/485), and the positive rate of CXCR4 in those without distant metastasis was 39.2% (256/653), the difference was statistically significant (RR=1.78, 95% CI 1.54-2.06, P < 0.01). The expression of CXCR4 was not related to the size and invasion of the primary tumor, the positive expression rates of CXCR4 in T1-T2 and T3-T4 patients were 41.0%(215/524) and 53.8%(84/156) (RR=0.71, 95% CI 0.60-0.84, P=0.053). The overall survival rate of patients with CXCR4-positive was lower than that of patients with CXCR4-negative, and the difference was statistically significant (30.1% vs. 66.9%, RR=0.45, 95% CI 0.30-0.61, P < 0.01). The disease-free survival rate of patients with CXCR4-positive was lower than that of patients with CXCR4-negative (38.0% vs. 20.1%, RR=1.89, 95% CI 1.45-2.47, P=0.002). Conclusions The pathological type, tumor staging and distant metastasis of NSCLC patients are correlated with CXCR4 expression level. The expression level of CXCR4 in tumor tissues has a predictive value for the prognosis of NSCLC patients; and the higher the expression level of CXCR4 is, the lower the overall survival and disease-free survival rates are. Key words: Carcinoma, non-small-cell lung; CXCR4; Prognosis; Meta-analysis

查看原文本刊更多论文

CXCR4表达与非小细胞肺癌患者临床病理特征及预后的相关性:meta分析

目的系统评价CXCR4与非小细胞肺癌(NSCLC)患者临床病理特征及预后的关系。方法计算机检索PubMed、EMbase、Cochrane Library、CNKI、万方、中国生物医学数据库，收集已公开发表的关于CXCR4表达与NSCLC预后相关性的队列研究。检索时间为数据库建立至2018年5月31日。文献筛选、数据提取及偏倚风险由2位审稿人独立完成，meta分析采用Stata 12.0软件进行。结果最终纳入20项研究，共纳入2 124例NSCLC患者。CXCR4在腺癌患者中的阳性表达率为51.8%(337/650)，在鳞状细胞癌患者中的阳性表达率为50.3%(224/445)，差异有统计学意义(RR=1.22, 95% CI 1.09 ~ 1.38, P=0.001)。Ⅰ~Ⅱ期CXCR4阳性表达率为41.1%(317/772)，Ⅲ~Ⅳ期CXCR4阳性表达率为57.0%(348/610)，差异有统计学意义(RR=0.62, 95% CI 0.55 ~ 0.69, P < 0.01)。有远处转移的患者CXCR4阳性表达率为55.3%(266 /485)，无远处转移的患者CXCR4阳性表达率为39.2%(256/653)，差异有统计学意义(RR=1.78, 95% CI 1.54 ~ 2.06, P < 0.01)。CXCR4的表达与原发肿瘤的大小和侵袭程度无关，T1-T2和T3-T4患者中CXCR4的阳性表达率分别为41.0%(215/524)和53.8%(84/156)(RR=0.71, 95% CI 0.60-0.84, P=0.053)。cxcr4阳性患者的总生存率低于cxcr4阴性患者，差异有统计学意义(30.1%比66.9%，RR=0.45, 95% CI 0.30 ~ 0.61, P < 0.01)。cxcr4阳性患者的无病生存率低于cxcr4阴性患者(38.0% vs. 20.1%， RR=1.89, 95% CI 1.45-2.47, P=0.002)。结论非小细胞肺癌患者的病理类型、肿瘤分期及远处转移与CXCR4表达水平相关。CXCR4在肿瘤组织中的表达水平对NSCLC患者的预后有预测价值;CXCR4表达水平越高，总生存率和无病生存率越低。关键词:肺癌，非小细胞肺;趋化因子受体CXCR4;预后;荟萃分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

肿瘤研究与临床 Medicine-Oncology

CiteScore

0.10

自引率

0.00%

发文量

7737

期刊介绍： "Cancer Research and Clinic" is a series of magazines of the Chinese Medical Association under the supervision of the National Health Commission and sponsored by the Chinese Medical Association. It mainly reflects scientific research results and academic trends in the field of malignant tumors. The main columns include monographs, guidelines and consensus, standards and norms, treatises, short treatises, survey reports, reviews, clinical pathology (case) discussions, case reports, etc. The readers are middle- and senior-level medical staff engaged in basic research and clinical work on malignant tumors.